DDInter986 DDInter899
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Isoniazid {u} (Compound) binds {v} (Gene) CYP3A4
Isoniazid {u} (Compound) causes {v} (Side Effect) Pyridoxine deficiency
Isoniazid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylprednisolone
Isoniazid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludrocortisone
Isoniazid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Isoniazid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Isoniazid {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Isoniazid (Compound) binds CYP3A4 (Gene)
Isoniazid (Compound) causes Pyridoxine deficiency (Side Effect)
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Isoniazid may lead to a major life threatening interaction when taken with Leflunomide